SARS-CoV-2 RNA polymerase as target for antiviral therapy
Abstract A new human coronavirus named SARS-CoV-2 was identified in several cases of acute respiratory syndrome in Wuhan, China in December 2019. On March 11 2020, WHO declared the SARS-CoV-2 infection to be a pandemic, based on the involvement of 169 nations. Specific drugs for SARS-CoV-2 are obvio...
Main Authors: | Luigi Buonaguro, Maria Tagliamonte, Maria Lina Tornesello, Franco M. Buonaguro |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://link.springer.com/article/10.1186/s12967-020-02355-3 |
Similar Items
-
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
by: Luigi Buonaguro, et al.
Published: (2020-05-01) -
Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example
by: Tornesello Maria, et al.
Published: (2007-05-01) -
Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies
by: Tagliamonte Maria, et al.
Published: (2011-01-01) -
Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
by: Anna Lucia Tornesello, et al.
Published: (2020-04-01) -
Selecting Target Antigens for Cancer Vaccine Development
by: Luigi Buonaguro, et al.
Published: (2020-10-01)